'Total Worldwide Revenues from Drugs to Treat Eye Disorders Will Reach $23.8bn in 2016' Predicts New Visiongain's Report

'Total Worldwide Revenues from Drugs to Treat Eye Disorders Will Reach $23.8bn in 2016' Predicts New Visiongain's Report PR Newswire LONDON, October 18, 2012 LONDON, October 18, 2012 /PRNewswire/ -- A new report by Visiongain predicts that total worldwide revenues from drugs to treat eye disorders will reach $23.8bn in 2016. Leading companies will achieve high sales growth from 2012 to 2022. That sales prediction and other forecasts appear in Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022, published in October 2012. Visiongain is a business information provider based in London, UK. The world market for ophthalmic drugs is a profitable segment of the healthcare market. The market for medicines to treat eye diseases is dominated by large pharma companies, which occupy five of the ten leading ophthalmic manufacturers' positions. The others participants are specialist companies, with three focused entirely on ophthalmic pharmaceutical products. In 2011, the top 10 ophthalmic drug manufacturers accounted for 70.6% of overall world revenues in this sector. US-based manufacturers dominate the ophthalmic drug industry and market, with a new entrant, Regeneron - with its recent launch of Eylea (for wet AMD) - rapidly establishing itself in that market. The overall ophthalmic medicines market is stimulated by a rising prevalence of eye disorders worldwide.